Q-omics provides the consensus-scored MCC profile across patient tissues and cancer cell-line models. MCC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MCC is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, MCC protein abundance shows 21,601 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, LUAD, and BRCA as cancer lineages where MCC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MCC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MCC survival associations across molecular data types. MCC RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MCC RNA expression–survival associations across cancer types. High MCC expression shows unfavorable associations in ACC, STAD, OV and HNSC, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MCC RNA expression.
This table summarizes MCC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MCC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MCC shows lower tumor expression in LUAD, LIHC, KIRC, KIRP and BRCA and higher tumor expression in HNSC. The LUAD box plot shows higher MCC RNA expression in normal versus tumor tissue (log2 FC = −0.881, t-test p < 0.001).
This table shows molecular features associated with MCC in patient tissues and cancer cell lines. In patient samples, MCC shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MCC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
